Related Experiment Videos
Triiodothyronine supplementation for hypothalamic obesity.
J K Fernandes1, M J Klein, Joann L Ater
1Department of Endocrinology and the Division of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Metabolism: Clinical and Experimental
|October 31, 2002
Summary
Triiodothyronine (T3) supplementation effectively treated hypothalamic obesity in three patients with suprasellar lesions. This thyroid hormone therapy promoted significant weight loss and improved overall well-being, offering a new treatment avenue.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Neuro-oncology
Background:
- Suprasellar lesions often lead to severe hypothalamic obesity and listlessness.
- Existing treatments, including nutritional counseling, have proven ineffective for this condition.
- Patients typically require management for associated conditions like diabetes insipidus and hypopituitarism.
Observation:
- Three patients with suprasellar lesions and significant weight gain were treated with triiodothyronine (T3) supplementation.
- Despite normal serum free thyroxine (T4) levels, patients exhibited symptoms of hypothalamic obesity.
- Previous nutritional interventions had failed to yield positive results.
Findings:
- T3 supplementation resulted in substantial weight loss across all three patients.
- One patient experienced improved bone mineral density.
- Patients reported enhanced overall well-being, including increased alertness and resolution of fatigue.
- Treatment was effective even at supraphysiologic T3 levels, with no reported adverse effects.
Implications:
- Triiodothyronine (T3) may represent a novel and effective therapeutic option for hypothalamic obesity.
- This approach could significantly improve the quality of life for patients with suprasellar lesions.
- Further research into T3 supplementation for similar endocrine-related obesity is warranted.